Navidea Biopharmaceuticals Inc (NYSEMKT:NAVB)

CAPS Rating: No stars

Caps

This ticker is not currently Ratable.

Add Stock to CAPS Watchlist

All Players

78 Outperform
22 Underperform
 

All-Star Players

7 Outperform
8 Underperform
 

Wall Street

6 Outperform
0 Underperform
 

Top NAVB Bull/Bear Pitches

The best Bull and Bear pitches based on recency and number of recommendations.

mkklaren1968 (< 20)
Submitted October 19, 2011

As of 10/19/11, Neoprobe's New Drug Application (NDA) for Lymphoseek® (tilmanocept) has been accepted for review by the FDA.

BuffettJunior1 (97.88)
Submitted October 16, 2011

Extremely overvalued trash stock.

NAVB VS S&P 500 (SPY)

Recent Community Commentary

Read the most recent pitches from players about NAVB.

Recs

0
Member Avatar BooDog2 (< 20) Submitted: 5/6/2015 12:12:01 PM : Outperform Start Price: $1.25 NAVB Score: -110.32

$NAVB basing near the $ once again. New management and great potential with their new platform under Goldberg. Gonzalez as the new CEO pushing the marketing potential for Lymphoseek. $2+ short term potential imo.

Recs

0
Member Avatar FlyinBlind (29.39) Submitted: 3/28/2015 9:32:05 AM : Underperform Start Price: $1.68 NAVB Score: +116.28

NAVB will outperform the market over the next 5 years, but due to its burn rate on R&D and G&A, it will go through a number of rounds of financing that will dilute out shareholders. This stock will excel, but there are stocks that are closer to monetizing shareholdeer value

Recs

0
Member Avatar minmartar (< 20) Submitted: 9/19/2014 1:00:18 AM : Outperform Start Price: $1.44 NAVB Score: -117.31

No competition.
Extremely undervalued.

Leaderboard

Find the members with the highest scoring picks in NAVB.

Score Leader

walt393

walt393 (99.91) Score: +228.70

The Score Leader is the player with the highest score across all their picks in NAVB.

Top
Pick
Member Name Member
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
Index
Gain
Score Commentary
capostatus 98.59 10/12/2010 Underperform 5Y $1.65 -84.50% +134.78% +219.27 0 Comment
stockjock11 < 20 3/26/2010 Underperform NS $1.72 -85.13% +132.35% +217.48 1 Comment
BuffettJunior1 97.88 10/17/2011 Underperform 5Y $3.02 -91.53% +124.81% +216.34 1 Comment
Europecv 29.37 11/23/2010 Underperform 5Y $1.82 -85.95% +130.19% +216.14 0 Comment
Caboverde 28.18 10/22/2010 Underperform 5Y $1.62 -84.21% +130.29% +214.50 0 Comment
SuperNova007 99.45 4/9/2010 Underperform 5Y $1.79 -85.71% +128.70% +214.41 0 Comment
TheChozen1 28.58 10/22/2010 Underperform 5Y $1.60 -84.01% +130.19% +214.20 0 Comment
walt393 99.91 12/15/2011 Underperform 5Y $2.46 -89.60% +121.25% +210.85 0 Comment
williamstep 98.58 6/3/2011 Underperform 5Y $4.70 -94.56% +109.14% +203.70 0 Comment
jrokket731 66.17 2/25/2011 Underperform 5Y $4.60 -94.44% +106.06% +200.50 0 Comment

Wall Street

See what the Wall Street professionals think, according to their public statements and filings.

Player Name Player
Rating
Start
Date
Call Time
Frame
Start
Price
Stock
Gain
S&P
Gain
Score End Date Commentary
TrackLadenburg < 20 11/7/2013 Outperform NS $1.46 -82.48% +53.35% -135.83 0 Comment
TrackUltraLong < 20 1/23/2013 Outperform NS $3.02 -91.53% +82.53% -174.06 1 Comment
TrackBurrillInst < 20 1/22/2013 Outperform NS $3.00 -91.47% +83.51% -174.98 0 Comment
TrackMorganJos 80.84 5/13/2011 Outperform NS $4.75 -94.61% +101.41% -196.02 0 Comment
trackwbbsecuriti < 20 5/5/2011 Outperform NS $4.55 -94.38% +103.01% -197.39 0 Comment
TrackRodmanRen < 20 2/14/2011 Outperform NS $3.40 -92.48% +104.62% -197.09 0 Comment

Advertisement